Skip to main content
HCPCS J0577 · Level II · Part B drug

J0577: buprenorphine extended-release (Brixadi (weekly dosing)), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J0577

Billing unit
Less than or equal to 7 days of therapy
Inj, brixadi, 7 days or less
ASP payment limit
$433.167
October 2026; +0.6% vs July 2026
Practitioner MUE
1
MAI 3
OPPS status
SI K
APC 0732
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J0577 is the Level II code for Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy, billed per Less than or equal to 7 days of therapy. The Medicare Part B ASP payment limit for October 2026 is $433.167 per billing unit, up 0.6% from July 2026. The practitioner MUE allows up to 1 units per date of service (MAI 3), so a full 1-unit day is $433.17 at the current limit. Under OPPS it carries status indicator K in APC 0732. J0577 is billed in units of Less than or equal to 7 days of therapy; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names buprenorphine extended-release: Q9991 (Sublocade from Indivior Inc.; billed in units of up to 100 mg); Q9992 (Sublocade from Indivior Inc.; billed in units of more than 100 mg). The ASP crosswalk maps 4 NDCs to it, sold as Brixadi (weekly dosing) by Braeburn Inc. No current Billing and Coding Article lists J0577, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J0577 at $433.167 per Less than or equal to 7 days of therapy for October 2026, derived from manufacturer average sales price plus 6%, compared with $430.576 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J0577
QuarterPayment limitPerCoinsurance
October 2026$433.167Less than or equal to 7 days of therapy20%
July 2026$430.576Less than or equal to 7 days of therapy—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 4 NDCs from 1 labeler to J0577. Report the NDC in the claim's drug segment and bill the number of J0577 units that equals the quantity administered divided by Less than or equal to 7 days of therapy; the last column gives units per full package.

NDCs that crosswalk to J0577
NDCDrug nameLabelerPackage sizeBilling units / package
58284-0208-01Brixadi (weekly dosing)Braeburn Inc.0.16 × 11
58284-0216-01Brixadi (weekly dosing)Braeburn Inc.0.32 × 11
58284-0224-01Brixadi (weekly dosing)Braeburn Inc.0.48 × 11
58284-0232-01Brixadi (weekly dosing)Braeburn Inc.0.64 × 11

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J0577. For practitioners the limit is 1 unit per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J0577 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services13 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital13 Date of Service Edit: ClinicalPrescribing Information
DME supplier13 Date of Service Edit: ClinicalPrescribing Information

MUE for J0577 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J0577 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J0577 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J0577 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J0577 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J0577 carries status indicator K and is assigned to APC 0732, with a published national unadjusted payment of $433.167. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J0577 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $433.17 per Less than or equal to 7 days of therapy, paid only when the drug is furnished integral to a covered surgical procedure. Pass-through status expires *.

Common denials for J0577 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J0577

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J0577

What does HCPCS code J0577 describe?

J0577 is defined by CMS as "Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy". Each billing unit represents Less than or equal to 7 days of therapy, so the units reported on the claim must equal the dose administered divided by that unit.

Is J0577 a CPT code?

No. J0577 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as buprenorphine extended-release (Brixadi (weekly dosing)); CPT codes are five-character codes maintained by the AMA. On a Part B claim J0577 reports the drug itself in less than or equal to 7 days of therapy units, and the administration is billed on its own line.

What is the Medicare reimbursement for J0577 in October 2026?

The ASP-based payment limit is $433.167 per Less than or equal to 7 days of therapy, with 20% beneficiary coinsurance. The July 2026 limit was $430.576. Commercial payers use their own fee schedules.

How many units of J0577 can be billed per day?

The practitioner Medically Unlikely Edit is 1 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J0577?

The October 2026 ASP crosswalk lists 4 NDCs from 1 labeler: Brixadi (weekly dosing) (Braeburn Inc.). For example NDC 58284-0208-01 (package size 0.16) equals 1 billing unit of J0577.

Does J0577 have NCCI bundling edits?

No active practitioner PTP pairs list J0577 as a column-1 or column-2 code in the v323r0 release.

J0577 vs Q9991: what is the difference?

Both are HCPCS Level II codes whose descriptor names buprenorphine extended-release. What sets Q9991 apart: Sublocade from Indivior Inc.; billed in units of up to 100 mg. J0577 is billed per less than or equal to 7 days of therapy, limit $433.167, MUE 1; Q9991 is billed per less than or equal to 100 mg, limit $2,060.132, MUE 1. Report the code whose descriptor matches the product and setting in the record.

J0577 vs Q9992: what is the difference?

Both are HCPCS Level II codes whose descriptor names buprenorphine extended-release. What sets Q9992 apart: Sublocade from Indivior Inc.; billed in units of more than 100 mg. J0577 is billed per less than or equal to 7 days of therapy, limit $433.167, MUE 1; Q9992 is billed per greater than 100 mg, limit $2,060.132, MUE 1. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.